Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Stage 0 includes: 0a (Ta, N0, M0); 0is (Tis, N0, M0). Ta: Noninvasive papillary carcinoma. Tis: Carcinoma in situ: "flat tumor". N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)
Biomarker and diagnostic research for non-invasive bladder urothelial carcinoma has been reported in the published literature.
4 clinical trials registered, 1 recruiting. Interventions under study include other interventions, biologic therapy, and drug therapy. Pipeline includes 2 PHASE3, 1 PHASE1. Research is sponsored by a mix of industry and academic institutions.
110 publications have been identified in PubMed for non-invasive bladder urothelial carcinoma. Research spans Diagnostic / Biomarker (35%), Review / Meta-Analysis (19%), and Basic Science / Preclinical (16%).
Research Type | Count | % of Total |
|---|---|---|
Testing and diagnosis research | 39 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 8:11 AM UTC
35%
Research summaries | 21 | 19% |
Laboratory research | 18 | 16% |
Patient case studies | 13 | 12% |
Clinical study results | 8 | 7% |
Disease patterns and progression | 8 | 7% |
New treatment approaches | 2 | 2% |
Other research | 1 | 1% |
Baycelebi D (2026). [PMID: 42118290](https://pubmed.ncbi.nlm.nih.gov/42118290/). *Virchows Arch*. [Diagnostic / Biomarker]
Shiozaki M (2026). [PMID: 41363059](https://pubmed.ncbi.nlm.nih.gov/41363059/). *International journal of urology : official journal of the Japanese Urological Association*. [Diagnostic / Biomarker]
Bilim V (2026). [PMID: 41893002](https://pubmed.ncbi.nlm.nih.gov/41893002/). *J Pers Med*. [Review / Meta-Analysis]
Kapriniotis K (2026). [PMID: 42042587](https://pubmed.ncbi.nlm.nih.gov/42042587/). *J Pers Med*. [Review / Meta-Analysis]
Farag MS (2026). [PMID: 41456876](https://pubmed.ncbi.nlm.nih.gov/41456876/). *Histopathology*. [Epidemiology / Natural History]
Fankhauser CD (2026). [PMID: 42016063](https://pubmed.ncbi.nlm.nih.gov/42016063/). *BJUI Compass*. [Diagnostic / Biomarker]
Eichenauer R (2026). [PMID: 41916385](https://pubmed.ncbi.nlm.nih.gov/41916385/). *Aktuelle Urol*. [Epidemiology / Natural History]
Kravchuk A (2026). [PMID: 42049549](https://pubmed.ncbi.nlm.nih.gov/42049549/). *Clin Genitourin Cancer*. [Basic Science / Preclinical]
Baptista D (2026). [PMID: 42022728](https://pubmed.ncbi.nlm.nih.gov/42022728/). *Cureus*. [Case Report / Case Series]
Tang C (2026). [PMID: 40996609](https://pubmed.ncbi.nlm.nih.gov/40996609/). *Int Urol Nephrol*. [Clinical Trial Publication]